Danaher (Leica) TCS SP5 Confocal System

丹纳赫（徕卡）TCS SP5 共焦系统

• 批准号: 7794242
• 负责人: ROBERT L MODLIN
• 金额: $ 49.09万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-13 至 2011-05-12
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7794242
• 关键词: Applied Research; Birds; Breathing; Cells; Centers for Disease Control and Prevention (U.S.); Communicable Diseases; Containment; Development; Disease; District of Columbia; Employment; Environment; Equipment; Funding; Goals; Grant; Housing; Image; Imagery; Investigation; Laboratories; Laser Microscopy; Lasers; Life; Microbe; Microscope; Morbidity - disease rate; Pathogenesis; Pennsylvania; Public Health; Reporting; Research; Research Personnel; Research Project Grants; Resolution; Route; Safety; Specimen; System; Time; Toxin; United States; United States Dept. of Health and Human Services; United States National Institutes of Health; biosafety level 3 facility; catalyst; microbial; microsystems; mortality; pathogen; prevent

DESCRIPTION (provided by applicant): A major cause of morbidity and mortality in the United States and throughout the world is infectious diseases. A major goal of the NIH is to "conduct and support basic and applied research to better understand, treat, and ultimately prevent infectious diseases". A key advance in the investigation of host-pathogen interactions has been the development of confocal laser microscopy, allowing the simultaneous visualization of different molecules both in real-time in living cells and in disease specimens. An obstacle to researchers studying infectious diseases is the ability to use confocal laser microscopy in facilities that allow the investigation of pathogens that cause "serious or potentially lethal disease through inhalation route exposure" and require Biosafety Level 3 (BSL3) containment (Biosafety in Microbiological and Biomedical Laboratories (BMBL), U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Institutes of Health, Fifth Edition, 2007.), or pathogens which have been declared by the Dept. of HHS and/or the USDA to have the "potential to pose a severe threat to public health and safety" and require Select Agent BSL3 facilities (Department of Health and Human Services, 42 CFR Parts 72 and 73, Office of Inspector General, 42 CFR 1003 Possession, Use and Transfer of Select Agents and Toxins; Final Rule, March 18, 2005). Here we propose the purchase of a Danaher (Leica) TCS SP5 Confocal System to be housed in a Select Agent BSL3 facility. Leica Microsystems is owned by the US company- Danaher Corporation. This confocal microscope will allow investigators studying host-microbe interactions to obtain multicolor imaging of live cells. In particular, UCLA has set aside space to house the Danaher (Leica) TCS SP5 Confocal System in a Select Agent BSL3 environment. This equipment grant will be the catalyst for researchers studying microbial pathogenesis to obtain new information, not presently obtainable at any facility at UCLA. A major benefit to our NIH funded research projects will be the ability to colocalize with high resolution specific host and pathogen molecules in real time, research that is presently not feasible. The facility will not only serve the eight major users on this grant, but will be open to anyone on the UCLA campus who requires the use of a confocal laser microscope in a BSL2 or 3 environment. The purchase of the Danaher (Leica) TCS SP5 Confocal System will allow UCLA researchers to make new advances which will help us understand, treat, and ultimately prevent infectious diseases. Leica is a subsidiary of Danaher, a US Company (NYSE: DHR). Danaher's headquarters are located on Pennsylvania Ave in Washington D.C. As of December 31, 2008, annual revenues were reported to be $12.7 billion. The company employs 50,300 people. The purchase of this microscope involves the employment of many in the US.

描述（由申请人提供）：在美国和全世界，发病率和死亡率的主要原因是传染病。NIH的一个主要目标是“进行和支持基础和应用研究，以更好地了解，治疗和最终预防传染病”。宿主-病原体相互作用研究的一个关键进展是共聚焦激光显微镜的发展，它允许在活细胞和疾病标本中实时同时观察不同的分子。研究传染病的研究人员面临的一个障碍是，在允许调查“通过吸入途径暴露导致严重或潜在致命疾病”的病原体并需要生物安全3级（BSL 3）控制的设施中使用共聚焦激光显微镜的能力（微生物和生物医学实验室（BMBL）的生物安全，美国卫生与公众服务部，疾病控制和预防中心和国立卫生研究院，第五版，2007年），或卫生部已申报的病原体美国卫生与公众服务部和/或美国农业部的规定，具有“对公众健康和安全构成严重威胁的可能性”，并要求特定制剂BSL 3设施（卫生与公众服务部，42 CFR第72和73部分，监察长办公室，42 CFR 1003特定制剂和毒素的拥有、使用和转移;最终规则，2005年3月18日）。在这里，我们建议购买丹纳赫（徕卡）TCS SP 5共聚焦系统，安装在Select Agent BSL 3设施中。徕卡显微系统公司由美国公司Danaher Corporation所有。这种共聚焦显微镜将使研究宿主-微生物相互作用的研究人员能够获得活细胞的显微成像。特别是，加州大学洛杉矶分校已经留出空间，以容纳丹纳赫（徕卡）TCS SP 5共聚焦系统在一个选择代理BSL 3环境。这项设备赠款将是研究微生物发病机理的研究人员获得新信息的催化剂，目前在加州大学洛杉矶分校的任何设施都无法获得。我们NIH资助的研究项目的一个主要好处是能够在真实的时间内与高分辨率特异性宿主和病原体分子共定位，这是目前不可行的研究。该设施将不仅为八个主要用户提供服务，而且将向加州大学洛杉矶分校校园内任何需要在BSL 2或3环境中使用共聚焦激光显微镜的人开放。购买Danaher（Leica）TCS SP 5共聚焦系统将使加州大学洛杉矶分校的研究人员取得新的进展，这将有助于我们了解，治疗，并最终预防传染病。徕卡是美国丹纳赫公司（纽约证券交易所代码：DHR）的子公司。丹纳赫的总部位于华盛顿的宾夕法尼亚大街，截至2008年12月31日，年收入为127亿美元。公司员工50，300人。购买这种显微镜涉及到美国许多人的就业。